WATCH: Corey S. Cutler, MD, MPH, FRCPC discusses the AGAVE-201 trial results for axatilimab in refractory chronic #GvHD and key factors to consider when assessing the data. Corey Cutler Dana-Farber

targetedonc.com/view/axatilima…

BREAKING: FDA approves nodapendekin alfa (Anktiva) for BCG-unresponsive non-muscle invasive bladder cancer. ow.ly/Hc6f50RlHXL

Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy. #BCSM | UCSF Helen Diller Family Comprehensive Cancer Ctr Hope Rugo

targetedonc.com/view/rugo-surv…

WATCH: Adam D. Cohen, MD, discusses ongoing research influencing the multiple #myeloma treatment landscape. #MMSM | Penn Medicine

targetedonc.com/view/car-t-and…

Gary J. Schiller, MD, of David Geffen School of Medicine at UCLA explains the red flag symptoms that increase suspicion of #BPDCN , the process for diagnosis, and any challenges with differential diagnosis.

targetedonc.com/view/improving…

The #FDA has granted a breakthrough therapy designation to ziftomenib for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia. #LEUSM

targetedonc.com/view/fda-grant…

According to Rhonda Henschel, MBA, community oncology practices looking to implement cellular therapy programs must address a number of challenges and considerations. The US Oncology Network Texas Oncology

targetedonc.com/view/optimizin…

Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with R/R advanced colorectal cancer. #CRCSM | MD Anderson Cancer Center

targetedonc.com/view/retrospec…

In patients with Epstein-Barr Virus+ relapsed/refractory #PTCL , treatment with nanatinostat and valganciclovir led to an ORR of 50% and a CR rate of 20% in the ITT population, according to topline data from the phase 2 NAVAL-1 trial.

targetedonc.com/view/positive-…

The phase 3 CONVERT trial comparing once-daily and twice-daily radiation therapy did not demonstrate the superiority of OD RT among patients with limited-stage #SCLC , suggesting 45 Gy BD should remain the standard of care in this patient population.

targetedonc.com/view/convert-t…

Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with #mRCC , and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines. #KCSM | Sumanta K. Pal, MD, FASCO City of Hope UC San Diego Health Rana McKay Thomas Hutson, DO, PharmD, FACP

targetedonc.com/view/case-1-th…

Gary J. Schiller, MD, of David Geffen School of Medicine at UCLA on Current Therapies and Strategies for Transplant-Ineligible #BPDCN Patients

targetedonc.com/view/current-t…

Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic #RCC . #kcsm | Cleveland Clinic
Shilpa Gupta

targetedonc.com/view/deciding-…

Biomarker testing has led to a change in treatment in this patient population, allowing targeted approaches to be used earlier and more aggressively. Edward S. Kim, MD, MBA, FACP, FASCO City of Hope City of Hopeoc

targetedonc.com/view/biomarker…

Establishing an assessment that incorporates radiomics may serve as a useful clinical tool for determining the risk of developing central lymph node metastasis in patients with clinically node-negative papillary thyroid microcarcinoma. #thycsm

targetedonc.com/view/establish…

Black patients with #mCSPC were less likely to be treated with novel treatments and were at a higher risk of death from their disease compared with White patients. #PCSM

targetedonc.com/view/new-study…

Gary Schiller, MD, David Geffen School of Medicine at UCLA discusses factors that make the transplant ineligible BPDCN patient population more difficult to treat, the major goals of therapy for these patients, & how the mechanism of action of tagraxofusp suggests potential efficacy.

targetedonc.com/view/challenge…

Gary J. Schiller, MD, will discuss the key clinical and pathologic features that distinguish #BPDCN from other malignancies, as well as the potential differential diagnoses that share a similar immunophenotype. David Geffen School of Medicine at UCLA

targetedonc.com/view/clinical-…

DNA- and RNA-based next-generation sequencing is the most crucial aspect in determining the right treatment option when assessing patients with thyroid cancer, according to Lova Sun Penn Medicine. #THYCSM

targetedonc.com/view/understan…

This segment delves into managing steroid-refractory #cGvHD , focusing on data from clinical trials involving agents such as ibrutinib and ruxolitinib. Mass General Cancer Center Catherine Lee Huntsman Cancer Institute UCLA Health

targetedonc.com/view/steroid-r…